0001019687-16-004862.txt : 20160119 0001019687-16-004862.hdr.sgml : 20160118 20160119061652 ACCESSION NUMBER: 0001019687-16-004862 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160119 DATE AS OF CHANGE: 20160119 EFFECTIVENESS DATE: 20160119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PharmaCyte Biotech, Inc. CENTRAL INDEX KEY: 0001157075 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 621772151 STATE OF INCORPORATION: NV FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-255391 FILM NUMBER: 161346887 BUSINESS ADDRESS: STREET 1: 12510 PROSPERITY DRIVE, SUITE 310 CITY: SILVER SPRING STATE: MD ZIP: 20904-1643 BUSINESS PHONE: (917) 595.2850 MAIL ADDRESS: STREET 1: 12510 PROSPERITY DRIVE, SUITE 310 CITY: SILVER SPRING STATE: MD ZIP: 20904-1643 FORMER COMPANY: FORMER CONFORMED NAME: NUVILEX, INC. DATE OF NAME CHANGE: 20090324 FORMER COMPANY: FORMER CONFORMED NAME: EFOODSAFETY COM INC DATE OF NAME CHANGE: 20010808 D 1 primary_doc.xml X0707 D LIVE 0001157075 PharmaCyte Biotech, Inc. 12510 PROSPERITY DRIVE, SUITE 310 SILVER SPRING MD MARYLAND 20904-1643 917-595-2850 NEVADA Nuvilex, Inc. NUVILEX, INC. EFOODSAFETY COM INC Corporation true Kenneth L Waggoner 12510 PROSPERITY DRIVE, SUITE 310 Silver Spring MD MARYLAND 20904 Executive Officer Director Chairman of the Board, Director, Chief Executive Officer, President and General Counsel Gerald W Crabtree 12510 PROSPERITY DRIVE, SUITE 310 Silver Spring MD MARYLAND 20904 Executive Officer Director Thomas Liquard 12510 PROSPERITY DRIVE, SUITE 310 Silver Spring MD MARYLAND 20904 Director Pharmaceuticals Decline to Disclose 06b false 2016-01-07 true true true true false 0 Chardan Capital Markets LLC 120128 None None 17 STATE STREET SUITE 1600 NEW YORK NY NEW YORK 10004 CO COLORADO NY NEW YORK false 3060000 1020000 2040000 Shows (i) proceeds from sale of 17 million shares of common stock and 17 million warrants (each to purchase 1 share of common stock with $.12 per share exercise price and 5 year exercise period) and (ii) proceeds if all warrants are exercised. false 2 30000 0 0 false PharmaCyte Biotech, Inc. /s/ Kenneth L. Waggoner Kenneth L. Waggoner Chief Executive Officer 2016-01-19